Benjamin Tsai says his initial plans – or the plans he’d been given – called on him being a doctor. But he quickly saw a greater opportunity working in the life sciences industry. Tsai made a quick run through consulting firms and business school before finding a place at Invus, an investment firm that has operated mostly out of the limelight. In this podcast, Tsai discusses his career, his outlook on Medtech and why Invus – investor in Auris Health and other high-profile deals – is beginning to get out to tell its own story.
Ben Tsai is a Partner at Invus Opportunities. Previously, Ben was a management consultant at the Monitor Group. Ben has an MBA from Harvard Business School and BS from the University of Southern California. He has served on over a dozen private company boards and currently lives in New York City with his wife and two children.
Invus Opportunities is a sister fund to The Invus Group, an equity investment firm founded in 1985 with over $8 billion of evergreen capital. Ben joined Invus Opportunities at its inception and has played a central role in developing its strategy, which focuses on partnering with market-leading management teams and investors in private transactions globally. With a differentiated heritage and capital base, Invus Opportunities brings a complementary dimension to growing companies and investor groups seeking to create lasting value. Invus Opportunities currently manages over $1.5 billion.
Meet Our Host
A follower and fan of medtech for nearly two decades, Tom Salemi is the former bureau chief, venture capital, at Elsevier Business Intelligence, where he oversaw coverage of venture investments in medtech.